BACKGROUND AND OBJECTIVES: Chronic kidney disease (CKD) is characterized by an exceptionally high mortality rate, primarily due to cardiovascular disease. Reduced soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels have been reported both in patients with subclinical atherosclerosis and CKD. DESIGN, PARTICIPANTS, & MEASUREMENTS: A cross-sectional study was conducted in 218 prevalent patients (121 men; 63 +/- 14 yr) undergoing hemodialysis (HD). sTWEAK levels in relation with the patients' outcome were studied. RESULTS: sTWEAK plasma levels were 208 [(165 to 272) pg/ml, median interquartile range], significantly lower than healthy controls (P < 0.0001). sTWEAK was negatively associated with inflammatory markers, such as C-reactive protein and IL-6. Overall mortality was assessed after an average follow-up of 31 mo, during which 81 patients died. After controlling for potential confounding variables, patients in the upper tertile of sTWEAK plasma levels had an increased risk of cardiovascular and all-cause mortality. A significant interaction effect between sTWEAK and IL-6 levels was found [synergy index: 2.19 (0.80, 5.93)]. Thus, the association of sTWEAK with mortality was strongest in patients with inflammation (defined as IL-6 > 7.0 pg/ml), in whom high sTWEAK strongly predicted cardiovascular and all-cause mortality. These results were confirmed in a second cohort of HD patients. CONCLUSIONS: The concurrent presence of elevated sTWEAK plasma concentrations and an inflammatory environment have additive effects on mortality in HD patients. Further studies on the potential different role of sTWEAK in health and disease are warranted.
BACKGROUND AND OBJECTIVES:Chronic kidney disease (CKD) is characterized by an exceptionally high mortality rate, primarily due to cardiovascular disease. Reduced soluble TNF-like weak inducer of apoptosis (sTWEAK) plasma levels have been reported both in patients with subclinical atherosclerosis and CKD. DESIGN, PARTICIPANTS, & MEASUREMENTS: A cross-sectional study was conducted in 218 prevalent patients (121 men; 63 +/- 14 yr) undergoing hemodialysis (HD). sTWEAK levels in relation with the patients' outcome were studied. RESULTS: sTWEAK plasma levels were 208 [(165 to 272) pg/ml, median interquartile range], significantly lower than healthy controls (P < 0.0001). sTWEAK was negatively associated with inflammatory markers, such as C-reactive protein and IL-6. Overall mortality was assessed after an average follow-up of 31 mo, during which 81 patients died. After controlling for potential confounding variables, patients in the upper tertile of sTWEAK plasma levels had an increased risk of cardiovascular and all-cause mortality. A significant interaction effect between sTWEAK and IL-6 levels was found [synergy index: 2.19 (0.80, 5.93)]. Thus, the association of sTWEAK with mortality was strongest in patients with inflammation (defined as IL-6 > 7.0 pg/ml), in whom high sTWEAK strongly predicted cardiovascular and all-cause mortality. These results were confirmed in a second cohort of HDpatients. CONCLUSIONS: The concurrent presence of elevated sTWEAK plasma concentrations and an inflammatory environment have additive effects on mortality in HDpatients. Further studies on the potential different role of sTWEAK in health and disease are warranted.
Authors: A Rashid Qureshi; Anders Alvestrand; José C Divino-Filho; Alberto Gutierrez; Olof Heimbürger; Bengt Lindholm; Jonas Bergström Journal: J Am Soc Nephrol Date: 2002-01 Impact factor: 10.121
Authors: P Saas; J Boucraut; P R Walker; A L Quiquerez; M Billot; S Desplat-Jego; Y Chicheportiche; P Y Dietrich Journal: Glia Date: 2000-10 Impact factor: 7.452
Authors: Y Chicheportiche; P R Bourdon; H Xu; Y M Hsu; H Scott; C Hession; I Garcia; J L Browning Journal: J Biol Chem Date: 1997-12-19 Impact factor: 5.157
Authors: Peter Stenvinkel; Christoph Wanner; Thomas Metzger; Olof Heimbürger; Francesca Mallamaci; Giovanni Tripepi; Lorenzo Malatino; Carmine Zoccali Journal: Kidney Int Date: 2002-11 Impact factor: 10.612
Authors: Alberto Ortiz; Ziad A Massy; Danilo Fliser; Bengt Lindholm; Andrzej Wiecek; Alberto Martínez-Castelao; Adrian Covic; David Goldsmith; Gültekin Süleymanlar; Gérard M London; Carmine Zoccali Journal: Nat Rev Nephrol Date: 2011-11-01 Impact factor: 28.314
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: Maureen McMahon; Brian J Skaggs; Jennifer M Grossman; Lori Sahakian; John Fitzgerald; Weng Kee Wong; Elaine V Lourenco; Nagesh Ragavendra; Christina Charles-Schoeman; Alan Gorn; George A Karpouzas; Mihaela B Taylor; Karol E Watson; Michael H Weisman; Daniel J Wallace; Bevra H Hahn Journal: Arthritis Rheumatol Date: 2014-01 Impact factor: 10.995
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2016-01-04 Impact factor: 8.237
Authors: Alper Azak; Mehmet Fatih Akdoğan; Nazım Denizli; Bülent Huddam; Gülay Koçak; Murat Gücün; Mustafa Adem Tatlısu; Recep Demirci; Bilal Yılmaz; Mehmet Dikeç; Murat Bakırtaş; Ibrahim Akdağ; Murat Duranay Journal: Int Urol Nephrol Date: 2013-09-17 Impact factor: 2.370
Authors: Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman Journal: Arthritis Res Ther Date: 2009-09-28 Impact factor: 5.156